Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)

BACKGROUND: No treatment demonstrated to improve survival in patients with recurrent glioblastoma (rGB) in a randomized trial. Combining axitinib with the programmed cell death ligand 1 blocking monoclonal antibody avelumab may result in synergistic activity against rGB. METHODS: Adult patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Awada, Gil, Ben Salama, Laila, De Cremer, Jennifer, Schwarze, Julia Katharina, Fischbuch, Lydia, Seynaeve, Laura, Du Four, Stephanie, Vanbinst, Anne-Marie, Michotte, Alex, Everaert, Hendrik, Rogiers, Anne, Theuns, Peter, Duerinck, Johnny, Neyns, Bart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570224/
https://www.ncbi.nlm.nih.gov/pubmed/33067319
http://dx.doi.org/10.1136/jitc-2020-001146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7570224/
https://www.ncbi.nlm.nih.gov/pubmed/33067319
http://dx.doi.org/10.1136/jitc-2020-001146

Ejemplares similares